- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.4: 7 residues within 4Å:- Chain A: E.181, L.231, N.232, G.348, V.416, S.417
- Ligands: NAG-NAG.7
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.12: 7 residues within 4Å:- Chain G: E.181, L.231, N.232, G.348, V.416, S.417
- Ligands: NAG-NAG.15
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN-MAN.20: 7 residues within 4Å:- Chain M: E.181, L.231, N.232, G.348, V.416, S.417
- Ligands: NAG-NAG.23
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.5: 5 residues within 4Å:- Chain A: N.332, T.341, N.355
- Ligands: NAG-NAG-BMA-MAN.6, NAG-NAG-BMA-MAN.6
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.13: 5 residues within 4Å:- Chain G: N.332, T.341, N.355
- Ligands: NAG-NAG-BMA-MAN.14, NAG-NAG-BMA-MAN.14
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.21: 5 residues within 4Å:- Chain M: N.332, T.341, N.355
- Ligands: NAG-NAG-BMA-MAN.22, NAG-NAG-BMA-MAN.22
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.6: 5 residues within 4Å:- Chain A: N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.5, NAG-NAG-BMA-MAN-MAN.5, NAG.33
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.14: 5 residues within 4Å:- Chain G: N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.13, NAG-NAG-BMA-MAN-MAN.13, NAG.46
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.22: 5 residues within 4Å:- Chain M: N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.21, NAG-NAG-BMA-MAN-MAN.21, NAG.59
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.8: 15 residues within 4Å:- Chain A: T.267, R.296, H.299, N.301, T.383
- Chain E: R.103, I.104, G.106, V.108
- Chain F: N.45, N.46, Q.47, P.61, D.62, I.63
2 PLIP interactions:1 interactions with chain A, 1 interactions with chain E- Hydrogen bonds: A:R.296, E:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.16: 15 residues within 4Å:- Chain G: T.267, R.296, H.299, N.301, T.383
- Chain K: R.103, I.104, G.106, V.108
- Chain L: N.45, N.46, Q.47, P.61, D.62, I.63
2 PLIP interactions:1 interactions with chain G, 1 interactions with chain K- Hydrogen bonds: G:R.296, K:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.24: 15 residues within 4Å:- Chain M: T.267, R.296, H.299, N.301, T.383
- Chain Q: R.103, I.104, G.106, V.108
- Chain R: N.45, N.46, Q.47, P.61, D.62, I.63
3 PLIP interactions:2 interactions with chain Q, 1 interactions with chain M- Hydrogen bonds: Q:G.106, Q:V.108, M:R.296
- 39 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.25: 3 residues within 4Å:- Chain A: E.57, N.58
- Chain B: S.17
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain A: N.103, R.113
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: N.204, T.206
Ligand excluded by PLIPNAG.28: 5 residues within 4Å:- Chain A: E.245, N.246
- Chain D: G.27, Y.28, Y.87
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: Q.263, N.265, S.303
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: N.271, I.292, V.412
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.308, S.362, W.364
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain A: N.324
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain A: S.357, N.361
- Ligands: NAG-NAG-BMA-MAN.6, NAG-NAG-BMA-MAN.6
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain A: K.199, N.211
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain B: N.100, S.102
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain B: N.126
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain D: T.20, R.61, W.63, E.66, N.68
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain G: E.57, N.58
- Chain H: S.17
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain G: N.103, R.113
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain G: N.204, T.206
Ligand excluded by PLIPNAG.41: 5 residues within 4Å:- Chain G: E.245, N.246
- Chain J: G.27, Y.28, Y.87
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain G: Q.263, N.265, S.303
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain G: N.271, I.292, V.412
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain G: N.308, S.362, W.364
Ligand excluded by PLIPNAG.45: 1 residues within 4Å:- Chain G: N.324
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain G: S.357, N.361
- Ligands: NAG-NAG-BMA-MAN.14, NAG-NAG-BMA-MAN.14
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain G: K.199, N.211
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain H: N.100, S.102
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain H: N.126
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain J: T.20, R.61, W.63, E.66, N.68
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain M: E.57, N.58
- Chain N: S.17
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain M: N.103, R.113
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain M: N.204, T.206
Ligand excluded by PLIPNAG.54: 5 residues within 4Å:- Chain M: E.245, N.246
- Chain P: G.27, Y.28, Y.87
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain M: Q.263, N.265, S.303
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain M: N.271, I.292, V.412
Ligand excluded by PLIPNAG.57: 3 residues within 4Å:- Chain M: N.308, S.362, W.364
Ligand excluded by PLIPNAG.58: 1 residues within 4Å:- Chain M: N.324
Ligand excluded by PLIPNAG.59: 4 residues within 4Å:- Chain M: S.357, N.361
- Ligands: NAG-NAG-BMA-MAN.22, NAG-NAG-BMA-MAN.22
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain M: K.199, N.211
Ligand excluded by PLIPNAG.61: 2 residues within 4Å:- Chain N: N.100, S.102
Ligand excluded by PLIPNAG.62: 1 residues within 4Å:- Chain N: N.126
Ligand excluded by PLIPNAG.63: 5 residues within 4Å:- Chain P: T.20, R.61, W.63, E.66, N.68
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zhang, P. et al., Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation. Cell Rep (2024)
- Release Date
- 2024-07-31
- Peptides
- Envelope glycoprotein gp120: AGM
Envelope glycoprotein gp41: BHN
3BNC117 heavy chain: CIO
3BNC117 light chain: DJP
10-1074 heavy chain: EKQ
10-1074 light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GG
AM
MB
BH
EN
NC
CI
FO
OD
DJ
IP
PE
HK
JQ
QF
LL
KR
R
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 39 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zhang, P. et al., Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation. Cell Rep (2024)
- Release Date
- 2024-07-31
- Peptides
- Envelope glycoprotein gp120: AGM
Envelope glycoprotein gp41: BHN
3BNC117 heavy chain: CIO
3BNC117 light chain: DJP
10-1074 heavy chain: EKQ
10-1074 light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GG
AM
MB
BH
EN
NC
CI
FO
OD
DJ
IP
PE
HK
JQ
QF
LL
KR
R